Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc., has entered into an agreement to acquire commercial operations and three manufacturing facilities in USA from Sandoz Inc., USA, a Novartis Division.
The acquisition will provide a unique opportunity to acquire a premier US generics business with a sizable and broad portfolio across key therapeutic areas. The acquisition is expected to be completed during the calendar year 2019.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
